Cardinal Health
CAH
$235.60
+2.42%
Cardinal Health, Inc. is a leading healthcare services company that distributes pharmaceuticals and medical-surgical products to pharmacies, hospitals, and other healthcare providers across the U.S. and internationally. As one of the 'Big Three' pharmaceutical wholesalers alongside Cencora and McKesson, it commands a dominant position in the U.S. pharmaceutical distribution market, with a complementary medical products segment. The current investor narrative centers on the company's ability to sustain growth amid a dynamic healthcare environment, highlighted by its recent earnings beat and raised full-year outlook, though revenue shortfalls have occasionally triggered market volatility. Additionally, its consistent dividend and strategic focus on specialty pharmaceuticals and nuclear pharmacy services are drawing attention as potential growth drivers.…
CAH
Cardinal Health
$235.60
Related headlines
Investment Opinion: Should I buy CAH Today?
Based on the analysis, I rate Cardinal Health as a Buy. The company's strong revenue growth, attractive PEG ratio of 0.30, and strong buy analyst consensus with an average target of $252.40 (9.7% upside) support this view. The core thesis is that CAH is a well-positioned healthcare distributor with accelerating top-line growth that is not fully reflected in its valuation.
Sign up to view all
CAH 12-Month Price Forecast
The AI model assesses Cardinal Health as a bullish opportunity, given its strong revenue growth, attractive valuation on a PEG basis, and positive analyst sentiment. The low beta and consistent dividend add to its appeal as a defensive growth stock. However, the medium confidence reflects the risks of thin margins and potential revenue volatility. The stance would be upgraded to high confidence if the company demonstrates sustained margin expansion and consistent revenue beats, while a downgrade would occur if growth decelerates or margins deteriorate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cardinal Health's 12-month outlook, with a consensus price target around $252.40 and implied upside of +7.1% versus the current price.
Average Target
$252.40
0 analysts
Implied Upside
+7.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$215 - $275
Analyst target range
The target price range spans from a low of $215.00 to a high of $275.00, representing a 27.9% spread between the lowest and highest estimates. The high target of $275 implies a 19.6% upside from the current price, likely assuming continued strong execution in the pharmaceutical distribution segment and successful margin expansion. The low target of $215 suggests a potential downside of 6.5%, possibly pricing in risks such as competitive pressures or regulatory changes. The relatively wide spread indicates moderate uncertainty about the company's future performance, but the overall bullish tilt suggests that analysts see more upside than downside. With no recent downgrades and multiple reaffirmations, the sentiment remains constructive, supporting the case for continued outperformance.
Bulls vs Bears: CAH Investment Factors
Cardinal Health presents a mixed picture: strong revenue growth, a compelling PEG ratio, and bullish analyst sentiment are countered by thin margins, a high trailing PE, and financial leverage. The bull case is currently stronger, supported by accelerating growth and a clear path to earnings expansion, but the stock's sensitivity to revenue misses and its low profitability margins introduce significant risk. The most important tension is whether the company can translate its top-line growth into sustainable margin expansion—if it does, the stock is undervalued; if not, the high valuation could compress.
Bullish
- Strong Revenue Growth: Q3 FY2026 revenue grew 11.1% YoY to $60.94B, accelerating from prior quarters. This top-line momentum is driven by the Pharmaceutical segment, which contributed $56.11B, and indicates robust demand for distribution services.
- Undervalued on PEG Ratio: With a PEG ratio of 0.30, the stock trades at a significant discount to its expected earnings growth. This suggests the market is not fully pricing in the company's growth potential, offering upside for value investors.
- Analyst Consensus Strong Buy: The average analyst target of $252.40 implies a 9.7% upside from the current price of $230.03. With a strong buy rating and no recent downgrades, analyst sentiment is firmly bullish.
- Consistent Dividend and Payout: CAH pays a dividend yield of 1.22% with a payout ratio of 31.6%, demonstrating a commitment to returning capital to shareholders. The recent dividend approval reinforces its status as a stable income stock.
Bearish
- Revenue Miss Triggers Selloff: In April 2026, the stock fell sharply after Q3 revenue missed Wall Street expectations, despite an earnings beat. This shows that even minor revenue shortfalls can cause outsized negative reactions, highlighting the market's sensitivity to top-line performance.
- Thin Profit Margins: Net margin is a razor-thin 0.70%, and operating margin is only 1.02%. This leaves little room for error; any cost pressure or pricing competition could severely impact profitability.
- High Valuation on Trailing PE: The trailing PE of 25.9x is elevated compared to the broader market and the company's own historical average. This suggests the stock may be priced for perfection, leaving limited upside if growth decelerates.
- Negative ROE and Debt Concerns: Return on equity is -56.1%, and the debt-to-equity ratio is -3.36, indicating significant leverage and financial risk. This could constrain financial flexibility and increase vulnerability to interest rate hikes.
CAH Technical Analysis
Cardinal Health's stock is in a robust long-term uptrend, with a 1-year price change of +48.2%, significantly outperforming the S&P 500's +18.2% over the same period. The current price of $230.03 sits near the upper end of its 52-week range, at approximately 94.6% of the distance from the 52-week low of $137.75 to the high of $243.21. This positioning near the highs suggests strong momentum and investor confidence, though it also raises the risk of overextension and a potential pullback.
Beta
0.52
0.52x market volatility
Max Drawdown
-20.6%
Largest decline past year
52-Week Range
$138-$243
Price range past year
Annual Return
+51.0%
Cumulative gain past year
| Period | CAH Return | S&P 500 |
|---|---|---|
| 1m | -1.4% | +1.7% |
| 3m | +19.6% | +4.7% |
| 6m | +13.9% | +10.4% |
| 1y | +51.0% | +21.9% |
| ytd | +14.5% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CAH Fundamental Analysis
Cardinal Health's revenue trajectory is robust, with the most recent quarter (Q3 FY2026, ended March 31, 2026) generating $60.94 billion, an 11.1% year-over-year increase. This growth is driven primarily by the Pharmaceutical segment, which contributed $56.11 billion in revenue, while the GMPD and Other segments added $3.15 billion and $1.71 billion, respectively. The multi-quarter trend shows consistent expansion, with revenue rising from $52.28 billion in Q1 FY2025 to $60.94 billion in Q3 FY2026, indicating accelerating growth. This top-line momentum underscores the company's ability to capitalize on market demand, though the low-margin nature of distribution means profitability is more critical to the investment case.
Quarterly Revenue
$60.9B
2026-03
Revenue YoY Growth
+11.1%
YoY Comparison
Gross Margin
4.1%
Latest Quarter
Free Cash Flow
$4.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CAH Overvalued?
Given that Cardinal Health is profitable, the price-to-earnings (PE) ratio is the primary valuation metric. The trailing PE is 25.9x, while the forward PE is 19.1x, implying the market expects significant earnings growth. The gap between trailing and forward PE suggests an anticipated EPS increase of approximately 35%, reflecting optimism about margin expansion and operational efficiency. This is supported by a PEG ratio of 0.30, which indicates that the stock is undervalued relative to its expected growth rate, a compelling signal for value-oriented investors.
PE
25.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 13x~42x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Cardinal Health operates with very thin margins—net margin is just 0.70% and operating margin is 1.02%—meaning any cost increase or pricing pressure can disproportionately impact earnings. The company's debt-to-equity ratio is -3.36, indicating negative equity, which is a red flag for financial stability, though this is partly due to share buybacks and accounting treatments. Additionally, the payout ratio of 31.6% and dividend yield of 1.22% suggest a commitment to shareholders, but this could strain cash flow if earnings decline. The negative ROE of -56.1% further underscores the fragility of its profitability metrics.